An Unusual Case of Extranodal Diffuse Large B-Cell Lymphoma Infiltrating Skeletal Muscle: A Case Report and Review of the Literature

Table 1

Clinical characteristics, diagnosis, treatment, and follow-up in 16 patients with muscle lymphoma diagnosed at our institution between 2000 and 2015.

Location/muscle	Age	Gender	Diagnosis	Treatment	Follow-up
Piriformis muscle	50	M	DLBCL	R-CHOP + RT	Alive in CR at 6 years
Thigh muscle	55	M	ALCL, ALK−	CHOP/ONTAK	Lost to follow-up
Iliacus muscle	52	M	DLBCL	R-CHOP	Died at 3 months
Psoas muscle	60	M	DLBCL	R-CE	Alive with PD at 28 months
Triceps muscle	79	M	DLBCL	R-CHOP	Alive in CR at 6 months
Psoas muscle	70	F	DLBCL	NR	NR
Sternothyroid muscle	57	F	DLBCL	R-CHOP + RT	Alive in CR at 14 years
Temporalis muscle	45	M	MZL	FCR	Alive in CR at 10 years
Cervical muscle	78	M	DLBCL	R-CHOP	Alive in CR at 10 years
Iliacus muscle	85	F	DLBCL	R-CHOP + RT	Died at 24 months
Buccal muscle	36	M	DLBCL	NR	Lost to follow-up
Right buccal	55	F	DLBCL	NR	Lost to follow-up
Buccal muscle	50	F	FL, low-grade	R-CHOP	Lost to follow-up
Strap muscle	42	F	HL	ABVD	Alive in CR at 10 years
Neck muscles	54	F	DLBCL	NR	Lost to follow-up
Neck muscles	79	F	MZL	NR	Lost to follow-up

ABVD = adriamycin, bleomycin, vinblastine, and dacarbazine; ALCL = anaplastic large T-cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP = cyclophosphamide, adriamycin, vincristine, and prednisone; CR = complete response; DLBCL = diffuse large B-cell lymphoma; F = female; FCR = fludarabine, cyclophosphamide, and rituximab; FL = follicular lymphoma; HL = Hodgkin lymphoma; M = male; MZL = marginal zone lymphoma; NR = not reported; ONTAK = denileukin diftitox; PD = progressive disease; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CE: rituxan-cytoxan-etoposide; RT = radiation therapy.